The post Personalized Medicine: 2021 FDA Guideposts for Progress – Focus On Diagnostics appeared first on �鶹ֱ�� & Lardner LLP.

The post Personalized Medicine: 2021 FDA Guideposts for Progress – Focus on Therapeutics appeared first on �鶹ֱ�� & Lardner LLP.

The post Coronavirus Innovation Guideposts on the Eve of the COVID-19 Pandemic appeared first on �鶹ֱ�� & Lardner LLP.

The post Collaborative Review of Scientific Evidence Announced By FDA appeared first on �鶹ֱ�� & Lardner LLP.

The post FDA Hits “Pause” on Regulation of LDTs appeared first on �鶹ֱ�� & Lardner LLP.

The post FDA Issues Draft Guidance To Streamline Regulatory Oversight Of NGS-Based Tests For Diagnosing Germline Diseases appeared first on �鶹ֱ�� & Lardner LLP.

The post FDA Oversight of Diagnostic Medicine – A Trap for the Unwary appeared first on �鶹ֱ�� & Lardner LLP.

The post FDA Considering New Regulatory Approaches for NGS – Part II appeared first on �鶹ֱ�� & Lardner LLP.

The post FDA Issues Draft Guidance for Regulation of LDTs appeared first on �鶹ֱ�� & Lardner LLP.

The post FDA’s Proposed Oversight of Laboratory Developed Tests – Industry Impact appeared first on �鶹ֱ�� & Lardner LLP.